FDA Panel Votes Against Omburtamab for Rare Pediatric Cancer ...Middle East

Medscape - News
The FDA's ODAC voted unanimously that there was a lack of evidence to support approval of l-omburtamab for a rare pediatric cancer. The FDA has a November 30 deadline to decide if it will approve the drug. Medscape Medical News

Hence then, the article about fda panel votes against omburtamab for rare pediatric cancer was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( FDA Panel Votes Against Omburtamab for Rare Pediatric Cancer )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News